Αρχική World News Genetic discovery could guide treatment for aggressive childhood cancer

Genetic discovery could guide treatment for aggressive childhood cancer

Researcher in a lab

Specific genetic changes in tumours are linked to how aggressive a rare childhood cancer will be, in a finding scientists say could help pave the way for new, tailored treatments.

The genetic changes identified in rhabdomyosarcoma – a type of muscle cancer that mostly affects children – were also linked to the patients’ age when the cancer developed and where it was found in the body. These factors affect how likely a child is to survive their disease.

This work is a fantastic example of how studying the underpinnings of children’s cancers can improve treatment choices.

– Sheona Scales, paediatric clinical trial lead at Cancer Research UK

Findings from this international study – the largest and most comprehensive of the disease to date – could lead to some children being offered more tailored, intensive treatment, while sparing others aggressive interventions.

The study was led by The Institute of Cancer Research (ICR), part-funded by Cancer Research UK, and is published in the Journal of Clinical Oncology.

“Children’s cancers are different to adult cancers. At Cancer Research UK, we are continuing to invest in improving our understanding of children and young people’s cancers to improve outcomes for our youngest cancer patients,” said Sheona Scales, paediatric lead at Cancer Research UK.

A breakthrough study

The international team analysed the DNA from 641 children and young people with rhabdomyosarcoma to look for changes that could be linked to how quickly the cancer grew and how likely it was to respond to treatment, amongst other things.

Researchers looked at the two main sub-types of the disease – fusion-gene positive and fusion-gene negative – separately.

The two main sub-types of rhabdomyosarcoma are fusion-gene positive and fusion gene-negative, depending on whether a so-called ‘fusion gene’ is present. A fusion gene is formed from two previously separate genes, which can affect how the cell functions.

When looking specifically at children with fusion-negative rhabdomyosarcoma, researchers found that tumours with faults in two specific genes – MYOD1 and TP53 – didn’t respond as well to treatment. These faults were also linked to worse survival.

Although the change in the TP53 gene was much rarer in children with fusion-positive rhabdomyosarcoma, it was still linked with worse survival. This has led researchers to classify this genetic fault as a ‘high risk’ indicator in both groups.

Study leader Professor Janet Shipley, Professor of Molecular Pathology at the ICR, said: “By looking at the genetic features of different tumours, we can divide children into different risk groups to help guide their treatment.”

Researchers are now planning to incorporate these new insights into the design of upcoming trials that aim to improve management of the disease.

Learning from the past and looking to the future

As well as uncovering new information, this study has challenged previous findings, including that the presence of a fault in a gene called RAS is linked to poor outcomes.

However, researchers did find that various RAS mutations appeared to be correlated with particular ages of onset for rhabdomyosarcoma. HRAS mutations arose in babies, KRAS mutations in toddlers and NRAS mutations in adolescence.

Data shows that babies have worse survival rates than older children, possibly because doctors avoid using more aggressive treatments like radiation.

Thanks to the findings of this study, researchers now believe that using targeted drugs such as tipifarnib, which blocks HRAS, may be particularly beneficial for young, high-risk patients.

“Children with aggressive and hard to treat cancer often undergo tough treatments that can cause long-term side-effects,” said Scales. “This work will hopefully lead to better outcomes for children with those types of cancers, not just in survival but in the impact their cancer treatment has upon the rest of their lives.”

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...